Home › Researcher directory › George M. Warimwe
George M. Warimwe
Affiliation : Kenya Medical Research Institute · KEMRI-Wellcome Trust Research Programme
- 62Publications (affiliation in Kenya)
Research profile
George M. Warimwe has 62 indexed publications (2007–2026). Their work appears mainly in “Wellcome Open Research”, “The Lancet Infectious Diseases” and “Vaccines”. Their most cited article, “Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors” (2020), has been cited 328 times. 5 of these publications date from the last three years of activity. Their work is co-authored with at least 12 researchers, including institutions in United Kingdom, United States, Sweden, South Africa.
Is this you? Get your research seen
Create your free DzCademia profile and add your articles: they will show up more easily on Google and in AI assistants like ChatGPT, so more people can read and cite your work.
Create my free profile Add my publicationsPublications (62)
- Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial
- Low-Dose Yellow Fever Vaccine in Adults in Africa
- Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial
- Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya
- Severe morbidity and hospital-based mortality from Rift Valley fever disease between November 2017 and March 2020 among humans in Uganda
- Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
- SARS‐CoV‐2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February–December 2022
- Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial
- Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial
- A Customizable Suite of Methods to Sequence and Annotate Cattle Antibodies
- Symptom prevalence and secondary attack rate of SARS‐CoV‐2 in rural Kenyan households: A prospective cohort study
- Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
- Clinical manifestations of Rift Valley fever in humans: Systematic review and meta-analysis
- Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya
- SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021
- Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020–21
- Transmission networks of SARS-CoV-2 in Coastal Kenya during the first two waves: A retrospective genomic study
- Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data
- Incidence of chikungunya virus infections among Kenyan children with neurological disease, 2014–2018: A cohort study
- The global burden of Chikungunya fever among children: A systematic literature review and meta-analysis
- Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya
- Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro
- Assessing the Level and Determinants of COVID-19 Vaccine Confidence in Kenya
- COVID-19 transmission dynamics underlying epidemic waves in Kenya
- Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya
- Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial
- Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021
- Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya
- Tracking the introduction and spread of SARS-CoV-2 in coastal Kenya
- Using cross-species vaccination approaches to counter emerging infectious diseases
- Endemic chikungunya fever in Kenyan children: a prospective cohort study
- Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya
- Quantifying previous SARS-CoV-2 infection through mixture modelling of antibody levels
- Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations
- Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
- Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data
- What Constitutes Protective Immunity Following Yellow Fever Vaccination?
- Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors
- Naturally Acquired Rift Valley Fever Virus Neutralizing Antibodies Predominantly Target the Gn Glycoprotein
- Urban Ecology of Arboviral Mosquito Vectors Along the Kenyan Coast
- Rift Valley fever: biology and epidemiology
- Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats
- Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components
- Congenital microcephaly unrelated to flavivirus exposure in coastal Kenya
- Complete Genome Sequences of Dengue Virus Type 2 Strains from Kilifi, Kenya
- Exploring Plasmodium falciparum Var Gene Expression to Assess Host Selection Pressure on Parasites During Infancy
- Systematic literature review of Rift Valley fever virus seroprevalence in livestock, wildlife and humans in Africa from 1968 to 2016
- A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus
- Association between Rift Valley fever virus seroprevalences in livestock and humans and their respective intra-cluster correlation coefficients, Tana River County, Kenya
- Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model
- Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology
- Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever
- Global selection of Plasmodium falciparum virulence antigen expression by host antibodies
- Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle
- Plasmodium falciparumantigenic variation: relationships between widespread endothelial activation, parasite PfEMP1 expression and severe malaria
- Plasmodium falciparum var Gene Expression Homogeneity as a Marker of the Host-Parasite Relationship under Different Levels of Naturally Acquired Immunity to Malaria
- Targets of antibodies against Plasmodium falciparum–infected erythrocytes in malaria immunity
- Prognostic Indicators of Life-Threatening Malaria Are Associated with Distinct Parasite Variant Antigen Profiles
- Plasmodium falciparum var gene expression is modified by host immunity
- Analysis of Immunity to Febrile Malaria in Children That Distinguishes Immunity from Lack of Exposure
- Haemoglobin C and S Role in Acquired Immunity against Plasmodium falciparum Malaria
- In Vitro Inhibition of Plasmodium falciparum Rosette Formation by Curdlan Sulfate
Publication venues
- Wellcome Open Research × 5
- The Lancet Infectious Diseases × 4
- Vaccines × 4
- BMC Infectious Diseases × 3
- PLoS ONE × 3
- Nature Communications × 3
Publications per year
- 20261
- 20252
- 20242
- 20237
- 202210
- 202115
- 20203
- 20196
- 20183
- 20172
Collaborations
Partner institutions : Ministry of Health · University of Oxford · Government of Kenya · London School of Hygiene & Tropical Medicine · Kenya National Blood Transfusion Services
Co-authors’ countries : United Kingdom · United States · Sweden · South Africa
Co-authors
- Philip Bejon
- John N. Gitonga
- Henry Karanja
- Lynette Isabella Ochola‐Oyier
- Charles N. Agoti
- Ambrose Agweyu
- Daisy Mugo
- James Nyagwange
- Edwine Barasa
- Kadondi Kasera
- J. Anthony G. Scott
- Benjamin Tsofa
Bibliographic data from OpenAlex (open database).
Why choose Dzcademia?
Profiles, articles and conference contributions: give your research a structured public presence. Integrated metadata help search engines and AI assistants identify your work and understand its references.
Comment with Google
Sign in with Google to comment directly on this page.